Clinical Trial Detail

NCT ID NCT02875067
Title Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors New York University School of Medicine
Indications

Hodgkin's lymphoma

non-Hodgkin lymphoma

Therapies

lenalidomide + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.